What did the COVID-19 epidemic learn psychiatrists?

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription Access

Abstract

The article is devoted to the analysis of the psychopathological consequences of the COVID-19 epidemic. Particular emphasis is placed on assessing the fact of increased mortality from COVID-19 in patients with schizophrenia and affective disorders. It is concluded that this was influenced by the irrational use of antipsychotics, which contributed to the appearance of diabetes and overweight in patients.

About the authors

Vladimir D. Mendelevich

Kazan State Medical University

Author for correspondence.
Email: mendelevich_vl@mail.ru
ORCID iD: 0000-0002-8476-6083
SPIN-code: 2302-2590
Scopus Author ID: 6602765981

M.D., D. Sci. (Med.), Prof., Head of the Depart., Depart. of Psychiatry and Medical Psychology

Russian Federation, Kazan

Foat F. Gatin

Kazan State Medical Academy — Branch of the Russian Medical Academy of Continuous Professional Education

Email: bagautdinowa.lejsan@yandex.ru
ORCID iD: 0000-0001-9528-8833
SPIN-code: 1567-9265
Scopus Author ID: 14024231600

M.D., D. Sci. (Med.), Prof., Head of the Depart., Depart. of Psychiatry and Forensic Psychiatric Examination

Russian Federation, Kazan

Rustem R. Khamitov

Kazan State Medical University

Email: psycheya.kzn@mail.ru
ORCID iD: 0000-0002-1271-8330
SPIN-code: 4923-9370

M.D., D. Sci. (Med.), Prof., Depart. of Psychiatry and Medical Psychology

Russian Federation, Kazan

References

  1. Poletti S, Palladini M, Mazza MG et al. Long-term consequences of COVID-19 on cognitive functioning up to 6 months after discharge: Role of depression and impact on quality of life. European Archives of Psychiatry and Clinical Neuroscience. 2022;272(5):773–782. doi: 10.1007/s00406-021-01346-9.
  2. Raina P, Wolfson Ch, Griffith L et al. A longitudinal analysis of the impact of the COVID-19 pandemic on the mental health of middle-aged and older adults from the Canadian Longitudinal Study on Aging. Nuture Aging. 2021;1:1137–1147. doi: 10.1038/s43587-021-00128-1.
  3. COVID-19 Mental Disorders Collaborators. Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic. Lancet Psychiatry. 2021;398:1700–1712. doi: 10.1016/S0140-6736(21)02143-7.
  4. Mosolov SN. Dlitel’nye psihicheskie narusheniya posle perenesennoĭ ostroĭ koronavirusnoĭ infekcii SARS-CoV-2. Sovremennaya terapiya psihicheskih rasstroĭstv. 2021;3:2–23. doi: 10.21265/PSYPH.2021.31.25.001.
  5. Mendelevich VD, Mullina NB. Sluchaj ostroj gipomanii pri COVID-19: povinen li koronavirus? Psihiatriya i psihofarmakoterapiya. 2020;22(5):51–54.
  6. Kozato N, Mishra M, Firdosi M. New-onset psychosis due to COVID-19. BMJ Case Rep. 2021;14:e242538. doi: 10.1136/bcr-2021-242538.
  7. Tariku M, Hajure M. Available evidence and ongoing hypothesis on corona virus (COVID-19) and psychosis: Is corona virus and psychosis related? A narrative review. Psychology Research and Behavior Management. 2020;13:701–704. doi: 10.2147/PRBM.S264235.
  8. Parra A, Juanes A, Losada CP et al. Psychotic symptoms in COVID-19 patients. A retrospective descriptive study. Psychiatry Research. 2020;291:113254. doi: 10.1016/j.psychres.2020.113254.
  9. Steardo LJr, Steardo L, Verkhratsky A. Psychiatric face of COVID-19. Translational Psychiatry. 2020;10:261. doi: 10.1038/s41398-020-00949-5.
  10. Rogers JP, Chesney E, Oliver D et al. Psychiatric and neuropsychiatric presentations associated with severe coronavirus infections: A systematic review and meta-analysis with comparison to the COVID-19 pandemic. Lancet Psychiatry. 2020;7:611–627. doi: 10.1016/S2215-0366(20)30203-0.
  11. Voitsidis P, Gliatas I, Bairachtari V et al. Insomnia during the COVID-19 pandemic in a Greek population. Psychiatry Research. 2020;289:113076. doi: 10.1016/j.psychres.2020.113076.
  12. Hartung TJ, Neumann Ch, Bahmer Th et al. Fatigue and cognitive impairment after COVID-19: A prospective multicentre study. eClinicalMedicine. 2022;53:101651. DOI: 10.1016/j. eclinm.2022.101651.
  13. Houben S, Bonnechère B. The impact of COVID-19 infection on cognitive function and the implication for rehabilitation: A systematic review and meta-analysis. Int J Environ Res Public Health. 2022;19:7748. doi: 10.3390/ijerph19137748.
  14. Hampshire A, Trender W, Chamberlain SR et al. A mehta cognitive deficits in people who have recovered from COVID-19. eClinicalMedicine. 2021;39:101044. doi: 10.1016/j.eclinm.2021.101044.
  15. Zhand N, Joober R. Implications of the COVID-19 pandemic for patients with schizophrenia spectrum disorders: Narrative review. BJPsych Open. 2021;7(e35):1–7. doi: 10.1192/bjo.2020.157.
  16. Mohan M, Perry BI, Saravanan P, Singh SP. COVID-19 in people with schizophrenia: Potential mechanisms linking schizophrenia to poor prognosis. Front Psychiatry. 2021;12:666067. doi: 10.3389/fpsyt.2021.666067.
  17. Fonseca L, Diniz E, Mendonca G et al. Schizophrenia and COVID-19: Risks and recommendations. Braz J Psychiatry. 2020;42(3):236–238. doi: 10.1590/1516-4446-2020-0010.
  18. Caqueo-Urizar A, Urzua A, Ponce-Correa F, Ferrer R. Psychosocial effect of the COVID-19 pandemic on patients with schizophrenia and their caregives. Frontiers on Psychology. 2021;12:729793. doi: 10.3389/fpsyg.2021.729793.
  19. Taquet M, Sillett R, Zhu L et al. Neurological and psychiatric risk trajectories after SARS-CoV-2 infection: An analysis of 2-year retrospective cohort studies including 1,284,437 patients. Lancet Psychiatry. 2022;9:815–827. DOI: 10.1016/ S2215-0366(22)00260-7.
  20. Bourmistrova NW, Solomon T, Braude Ph et al. Long-term effects of COVID-19 on mental health: A systematic review. J Affect Disord. 2022;299:118–125. doi: 10.1016/j.jad.2021.11.031.
  21. Brown EE, Kumar S, Rajji TK et al. Anticipating and mitigating the impact of the COVID-19 pandemic on Alzheimer’s disease and related dementias. Am J Geriatric Psychiatry. 2020;28(7):712–721. doi: 10.1016/j.jagp.2020.04.010.
  22. Fond G, Nemani K, Etchecopar-Etchart D, Loundou A. Association between mental health disorders and mortality among patients with COVID-19 in 7 countries; A systematic review and meta-analysis. JAMA Psychiatry. 2021;78(11):1208–1217. doi: 10.1001/jamapsychiatry.2021.2274.
  23. Dembosky A. Having schizophrenia is the second biggest risk factor for dying from COVID-19. Connecticut Public. 20 March 2022. https://www.ctpublic.org/2022-03-20/having-schizophrenia-is-the-second-biggest-risk-factor-for-dying-from-covid-19 (access date: 02.12.2022).
  24. Nemani K, Li Ch, Olfson M et al. Association of psychiatric disorders with mortality among patients with COVID-19. JAMA Psychiatry. 2021;78(4):380–386. doi: 10.1001/jamapsychiatry.2020.4442.
  25. Kepinska AP, Lyegbe CO, Vermon AC et al. Schizophrenia and influenza at the centenary of the 1918–1919 Spanish influenza pandemic: Mechanisms of psychosis risk. Front Psychiatry. 2020;11:72. doi: 10.3389/fpsyt.2020.00072.
  26. Menninger KA. Influenza and schizophrenia. An analysis of post-influenzal “dementia precox” as of 1918, and five years later. The American Journal of Psychiatry. 2006;82(4):469–529. doi: 10.1176/ajp.82.4.469.
  27. Brown AS, Begg MD, Gravenstein S et al. Serologic evidence of prenatal influenza in the etiology of schizophrenia. Arch Gen Psychiat. 2004;61:774–780. doi: 10.1001/archpsyc.61.8.774.
  28. Pearce BD. Schizophrenia and viral infection during neurodevelopment: A focus on mechanisms. Mol Psychiat. 2001;6:634–646. doi: 10.1038/sj.mp.4000956.
  29. Magalhães D, Ferreira F, Ferreira T et al. Influenza and schizophrenia: How can we shed a light in the new virus from an old association? European Psychiatry. 2021;64:168. doi: 10.1192/j.eurpsy.2021.447.
  30. Fusick AJ, Gunther S, Sullivan G. The anti-vaccination movement: when does a belief become delusional? Journal of Public Health. 2021;29:1301–1302. doi: 10.1007/s10389-020-01244-9.
  31. Bitan DT, Kridin K, Cohen AD, Weinstein O. COVID-19 hospitalisation, mortality, vaccination, and postvaccination trends among people with schizophrenia in Israel: A longitudinal cohort study. Lancet Psychiatry. 2021;8:901–908. DOI: 10.1016/ S2215-0366(21)00256-X.
  32. Bitan DT. Patients with schizophrenia are under-vaccinated for COVID-19: A report from Israel. World Psychiatry. 2020;20(2):300–301. doi: 10.1002/wps.20874.
  33. Nakhaee H, Zangiabadian M, Bayati R et al. The effect of antidepressants on the severity of COVID-19 in hospita- lized patients: Systematic review and meta-analysis. PLoS One. 2022;17(10):e0267423. doi: 10.1371/journal.pone.0267423.
  34. Clelland CL, Ramiah K, Steinberg L, Clelland GD. Analysis of the impact of antidepressants and other medications on COVID-19 infection risk in a chronic psychiatric in-patient cohort. BJPsych Open. 2021;8(1):e6. doi: 10.1192/bjo.2021.1053.
  35. Ekinci O. Do we need to change our treatment approach to schizophrenia during the COVID-19 pandemic? Int J Clin Pract. 2021;75:e14013. doi: 10.1111/ijcp.14013.
  36. Pardamean E, Roan W, Amartini Iskandar KT et al. Mortality from coronavirus disease 2019 (COVID-19) in patients with schizophrenia: A systematic review, meta-analysis and meta-regression. Gen Hosp Psychiatry. 2022;75:61–67. doi: 10.1016/j.genhosppsych.2022.01.010.
  37. Holt RIG. Association between antipsychotic medication use and diabetes. Curr Diab Rep. 2019;19(10):96. doi: 10.1007/s11892-019-1220-8.
  38. Azevedo da Silva M, Fournier A, Boutron-Ruault MC et al. Increased risk of type 2 diabetes in antidepressant users: evidence from a 6-year longitudinal study in the E3N cohort. Diabetic Medicine. 2020;37(11):1866–1873. doi: 10.1111/DME.14345.
  39. Wharton S, Raiber L, Serodio KJ et al. Medications that cause weight gain and alternatives in Canada: A narrative review. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy. 2018;11:427–438. doi: 10.2147/DMSO.S171365.
  40. Miidera H, Enomoto M, Kitamura S et al. Association between the use of antidepressants and the risk of type 2 diabetes: A large, population-based cohort study in Japan. Diabetes Care. 2020;43:885–893. doi: 10.2337/dc19-1175.
  41. Gafoor R, Booth HP, Gulliford MC. Antidepressant utilisation and incidence of weight gain during 10 years’ follow-up: population based cohort study. BMJ. 2018;23(361):k1951. doi: 10.1136/bmj.k1951.
  42. Reis G, dos Santos Moreira-Silva EA, Medeiros Silva DC et al. Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: The TOGETHER randomised, platform clinical trial. Lancet Glob Health. 2022;10:e42–51. DOI: 10.1016/ S2214-109X(21)00448-4.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download
2. Fig. 1. Persistence of clinically significant fatigue and cognitive impairment 9 months after COVID-19 [12].

Download (79KB)
Indexing metadata
3. Fig. 2. The risk of becoming overweight when using various antidepressants [41].

Download (121KB)
Indexing metadata

Copyright (c) 2023 Mendelevich V.D., Gatin F.F., Khamitov R.R.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies